Medicus Pharma to Present Teverelix Phase 1 Data at Endocrinology Conference

Apr 15, 2026

Medicus Pharma (NASDAQ: MDCX) will present new Phase 1 clinical data for Teverelix at the American Association of Clinical Endocrinology meeting in Las Vegas. The investigational therapy is a long-acting GnRH antagonist being developed for hormone-driven conditions.

The data, derived from two studies involving 48 healthy premenopausal women, will support potential applications in women’s health, including endometriosis and uterine fibroids, as the company continues to expand its clinical pipeline.

#MedicusPharma
#MDCX
#Biotech
#ClinicalTrials
#WomensHealth
#Endometriosis
#UterineFibroids
#DrugDevelopment
#HealthcareInnovation
#MedicalResearch
#Pharmaceuticals
#Endocrinology
#BiotechInvesting
#JaneKing
#NewsOut